SELLAS (SLS) is a publicly traded Healthcare sector company. As of May 21, 2026, SLS trades at $8.91 with a market cap of $1.36B and a P/E ratio of -35.77. SLS moved +18.58% today. Year to date, SLS is +79.40%; over the trailing twelve months it is +362.37%. Its 52-week range spans $0.77 to $9.10. Analyst consensus is buy with an average price target of $10.00. Rallies surfaces SLS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
SELLAS Life Sciences Hits 72 of 80 Trial Events and Doses First AML Patient with $114M Cash: SELLAS Life Sciences ended 2025 with $71.8 million in cash and cash equivalents and has secured an additional $42.6 million in Q1 2026 warrant proceeds, bolstering its financial runway. The company has recorded 72 of 80 events in its pivotal Phase 3 REGAL trial and dosed the first patient in its Phase 2 SLS009 expansion for newly diagnosed AML.
| Metric | Value |
|---|---|
| Price | $8.91 |
| Market Cap | $1.36B |
| P/E Ratio | -35.77 |
| EPS | $-0.25 |
| Dividend Yield | 0.24% |
| 52-Week High | $9.10 |
| 52-Week Low | $0.77 |
| Volume | 300.81K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-26.86M |
| Gross Margin | 0.00% |
2 analysts cover SLS: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $10.00.